CKLSF (CK Life Sciences International Holdings) LT-Debt-to-Total-Asset: 0.35 (As of Dec. 2025)

What is CK Life Sciences International Holdings LT-Debt-to-Total-Asset?

CK Life Sciences International Holdings CKLSF +28.57% 34 LT-Debt-to-Total-Asset is 0.35 as of Dec. 2025. GuruFocus rates CKLSF with a GF Score™ of 34/100 and a GF Value™ of $0.11. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CK Life Sciences International Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.35.

CK Life Sciences International Holdings's long-term debt to total assets ratio declined from Dec. 2024 (0.44) to Dec. 2025 (0.35). It may suggest that CK Life Sciences International Holdings is progressively becoming less dependent on debt to grow their business.

CK Life Sciences International Holdings (OTCPK:CKLSF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CK Life Sciences International Holdings LT-Debt-to-Total-Asset Related Terms

CK Life Sciences International Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for CK Life Sciences International Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CK Life Sciences International Holdings LT-Debt-to-Total-Asset Chart

CK Life Sciences International Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.42

0.25

0.42

0.44

0.35

CK Life Sciences International Holdings Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.42	0.35	0.44	0.47	0.35

34GF Score

CK Life Sciences International Holdings Inc CKLSF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CK Life Sciences International Holdings LT-Debt-to-Total-Asset Calculation

CK Life Sciences International Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	536.282	/	1521.253
	=	0.35

CK Life Sciences International Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	536.282	/	1521.253
	=	0.35

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.35 mean?

CK Life Sciences International Holdings (CKLSF) has a LT-Debt-to-Total-Asset of 0.35 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CK Life Sciences International Holdings and its competitors.

Is CK Life Sciences International Holdings' LT-Debt-to-Total-Asset too high?

CK Life Sciences International Holdings' current LT-Debt-to-Total-Asset is 0.35. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.

How does CK Life Sciences International Holdings' LT-Debt-to-Total-Asset compare to VRTX and REGN?

CK Life Sciences International Holdings' LT-Debt-to-Total-Asset of 0.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on CK Life Sciences International Holdings and its competitors. CK Life Sciences International Holdings's current LT-Debt-to-Total-Asset is 0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CK Life Sciences International Holdings stock overvalued right now?

CK Life Sciences International Holdings (CKLSF) has a current LT-Debt-to-Total-Asset of 0.35. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.35. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current LT-Debt-to-Total-Asset is 0.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?

Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued. The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.

Key valuation signals for CKLSF:

LT-Debt-to-Total-Asset: 0.35
GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CK Life Sciences International Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies HKSE:02256 HKSE:02157 HKSE:02659 HKSE:06826 HKSE:09966 HKSE:02105 HKSE:02591 HKSE:01477 HKSE:02142 HKSE:06938 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 00775:Hong Kong

Address 2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong, HKG

Website https://www.ck-lifesciences.com

CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.

34GF Score

Get the complete analysis for CKLSF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09

Price

$0.11

GF Value

View CKLSF Analysis

See LT-Debt-to-Total-Asset data for all stocks →